The Treatment of Ovarian Cancer by a Multimodality Approach: Remission Induction with Chemotherapy – Hexa PAMP and PAMP Regimens – Followed by Whole-abdominal Radiation

Goldhirsch, Aron; Greiner, Richard; Dreher, E.; Locher, Gottfried W.; Davis, Ben; Reinhard, Jacqueline; Joss, R; Brunner, K. W.

doi:10.1159/000215691

Cited by 5 publications

(3 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…All patients were eligible for treatment with cisplatin (P), mclphalan (PAM), and or hexamethyl melamine (llcxa) in a prospective trial (PAMP with or without HLXA-PAMP) [21]. The sera of these patients were used to analyze the correlation between the markers and the bulk of the disease.…”

Section: Methodsmentioning

confidence: 99%

“…CA-125 [8], GT [14,15], and SA [16] have been identilied and measured and their relationships to tumor bulk studied [17][18][19], The response to cytotoxic treatment of patients with primarily elevated serum CA-125 [8,21] or GT [14,15] has been reported. A decrease in the levels to below the threshold con sidered within the range of concentrations seen in the normal population did not.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Ovarian Cancer and Tumor Markers: Sialic Acid, Galactosyltransferase and CA-125

et al. 1988

Self Cite

View full text Add to dashboard Cite

In an effort to correlate the serum values of potential markers, including CA-125, galactosyltransferase, and total sialic acid, with residual tumor mass after initial surgery, 43 patients with FIGO stage lib and c, III and IV ovarian cancer were studied. The sensitivity of galactosyltransferase and siliac acid levels was sufficient to correlate their serum values with the corresponding residual tumor mass. Furthermore, 28 patients were histopathologically evaluated for their response to chemotherapy. Determination of these tumor markers did not permit discrimination between small residual disease (≤1 cm) and a state of ‘no evidence of disease’. Conversely, progression of disease has been associated with a sensitive increase in the level of all three markers. CA-125 has been found to be the most useful of the three for distinguishing between responders and nonre-sponders.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Ovarian Cancer and Tumor Markers: Sialic Acid, Galactosyltransferase and CA-125

et al. 1988

Self Cite

View full text Add to dashboard Cite

show abstract

“…Ungefähr ein Drittel der postopera tiv nicht tumorfreien, aber kurativ behandelten Patientinnen wird mit der Chemotherapie in eine histologisch bestätigte komplette Remission gebracht [1, 10,13,14,22,27,30]. Die hohen Rezidivraten führten zur Anwendung der Ganzabdo menbestrahlung als Konsolidierungstherapie im Anschluß an die Second-look-Laparotomie [11,15,23,29].…”

Section: Introductionunclassified

Die Ganzabdomenbestrahlung nach Kombinationschemotherapie und Second-look-Laparotomie bei der Behandlung des fortgeschrittenen Ovarialkarzinoms

et al. 1985

Self Cite

View full text Add to dashboard Cite

Zwischen 1980 und 1984 wurden 54 Patientinnen mit fortgeschrittenem Ovarialkarzinom, die nach Operation und anschließender Chemotherapie mit Alkeran (n = 7) oder Cis-Platin/Alkeran ± Hexa-methylmelamin (n = 47) sowie Second-look-Laparotomie behandelt worden waren, entweder mit der Moving-strip-Technik (n = 35) oder später mit der Open-field-Technik (n = 19) nachbestrahlt. 32 Patientinnen kamen in CR zur Nachbestrahlung. 15 CR-Patientinnen waren nach Open-field-Bestrahlung und mittlerer Beobachtungszeit von 25 Monaten rezidivfrei. Zu diesem Zeitpunkt hatten von 17 Patientinnen mit Moving-strip-Bestrahlung 5 Rezidive. Die Rezidivhäufigkeit geht offenbar zu Lasten der sehr langen Bestrahlungszeit und häufiger Therapieunterbrechung. Waren zum Bestrahlungsbeginn Resttumoren vorhanden, konnte durch eine Strahlentherapie eine CR nur dann erreicht werden, wenn lediglich eine Alkeran-Monotherapie vorangegangen war.

show abstract

Vasoconstrictive effect of topical timolol on human retinal arteries

Martin

Rabineau

1989

Graefe's Arch Clin Exp Ophthalmol

View full text Add to dashboard Cite

Timolol is widely used in glaucoma treatment without sufficient knowledge of its vascular retinal effects. In this study, we measured the retinal vessel diameters before and after instillation of 0.5% timolol twice daily in one eye for 1 week, using photographic enlargements (x44). A total of 12 normal, caucasian subjects aged 25-39 years (average, 30.6 +/- 4.2 years) participated in this study. In all, 75% of the subjects had a diminution of retinal arterial size in the treated eye. The mean arterial diametric decrease was 4.1% in treated eyes compared with both untreated eyes and pretreatment values of treated eyes. These diminutions were statistically significant according to Student's paired t-test (P less than 0.05). No statistical difference was found in venous diameters (t = -0.065). Results showed that 0.5% timolol may have a vasoconstrictive effect on the retinal arteries of normal human subjects after 1 week of unilateral instillation twice daily. We suggest that this arterial vasoconstriction could be caused by the effect of timolol on the vascular beta-2 receptors. Further investigations are warranted to determine whether timolol also acts on ciliary arteries and whether arterial vasoconstriction participates in lowering intraocular pressure.

show abstract

The Treatment of Ovarian Cancer by a Multimodality Approach: Remission Induction with Chemotherapy – Hexa PAMP and PAMP Regimens – Followed by Whole-abdominal Radiation

Cited by 5 publications

References 4 publications

Ovarian Cancer and Tumor Markers: Sialic Acid, Galactosyltransferase and CA-125

Ovarian Cancer and Tumor Markers: Sialic Acid, Galactosyltransferase and CA-125

Die Ganzabdomenbestrahlung nach Kombinationschemotherapie und Second-look-Laparotomie bei der Behandlung des fortgeschrittenen Ovarialkarzinoms

Vasoconstrictive effect of topical timolol on human retinal arteries

Contact Info

Product

Resources

About